This page shows the latest Opko news and features for those working in and with pharma, biotech and healthcare.
It’s not the first long-acting hGH to miss the mark in trials - earlier this year Pfizer and Opko’s once-weekly candidate also failed a phase III trial.
Pfizer and partner Opko ended 2016 on a disappointing note after their long-acting drug for growth hormone deficiency failed a phase III trial. ... Opko put a brave face on the finding, saying it could have been skewed by "one or more outliers" that
No financial details of the deal have been disclosed. This rounds off a busy M&A period for Pfizer which just a fortnight ago partnered with Opko Health on a late
TTR. TTR-mediated amyloidosis. I. TKM-ApoB. Tekmira. ApoB. hypercholesterolaemia. Stalled. bevasiranib. Opko Health.
Opko Health is developing bevasiranib for the treatment for wet age-related macular degeneration (AMD). ... In phase II trials, bevasiranib inhibited the growth of choroidal neovascularisation and Opko have now initiated a pivotal phase III trial that
Acuity plans to initiate its phase III programme in 2007 and in March the company agreed a merger with several partners to establish a publicly-traded company, Opko. ... If the trial goes as hoped, Opko may lead the race to reach the market with a siRNA
More from news
Approximately 1 fully matching, plus 5 partially matching documents found.
The manufacturing CRLs have been out in force and AstraZeneca is not the only company on the receiving end with OPKO receiving a CRL earlier in the year [March] in relation ... 293. OPKO Health/ Vifor Fresenius. Licence. Rayaldee in EP, CA, Mexico,
Opko's strategy in its $1.47bn acquisition of Bio-Reference Laboratories at $52.58 per share (approximately 60% premium) is to gain access to a range of diagnostic capabilities including ... Acquisition - company. 2, 050. Bio-Reference Laboratories/ OPKO
This product, named hGH-CTP, was in the portfolio of Prolor Biotech which Opko acquired in August 2013 for $480m. ... The upfront payment of $295m from Pfizer will go some of the way to recoup the price Opko paid for Prolor.
Collaboration, licence. 581. Opko Health / Pfizer. Long-acting hGH-CTP for growth hormone deficiency in adults and children (p3).
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Prior to this, Dr Freedman served as GlaxoSmithKline's vice president of oncology R&D, and led OPKO Health's R&D department.
Dr Douglass Laidlaw brings experience from Relypsa and Sanofi. Miami-based OPKO Health has appointed Dr Douglass Laidlaw as vice president of medical affairs. ... Philip Frost, chairman and chief executive of OPKO, said: “Doug is a key addition to the
More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.
The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...